We are live on ! Find out more

CG Oncology

CGON

Market cap $6.62B

74.67 USD

+0.34

0.46%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

74.67

0.00

0%

1 day

0.46%

5 days

0.78%

1 month

4.58%

3 months

33.13%

6 months

21.28%

Year to date

78.68%

1 year

141.34%

5 years

100.89%

10 years

100.89%

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 142

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 58.3%

Negative 8.3%

Schaeffers Research

15 Stocks to Watch With Short Squeeze Potential

Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.

15 Stocks to Watch With Short Squeeze Potential

CG Oncology to Present at Upcoming Investor Conferences in September

DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:

CG Oncology to Present at Upcoming Investor Conferences in September

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

CG Oncology: Circling Back After Huge Rally

CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.

CG Oncology: Circling Back After Huge Rally

Zacks Investment Research

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago.

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

Zacks Investment Research

CG Oncology Stock Gains 12% in Three Months: What's Driving It?

CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.

CG Oncology Stock Gains 12% in Three Months: What's Driving It?

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-muscle invasive bladder cancer, or NMIBC.

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

See News Rankings

Price charts implemented using Lightweight Charts™